Japan Patent Office grants first patent covering Histotype Px®
OSLO – May 28, 2025 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that Japanese patent number 7670691 has been granted by the Japan Patent Office (JPO).
This is the first patent granted in Japan and the second in Asia, further strengthening the global IP protection of DoMore Diagnostics’ AI-based Histotype Px® digital biomarkers. Histotype Px is being tested by leading clinicians and researchers in Japan, with groundbreaking data on Japanese patients in the Galaxy trial presented at last year’s European Society for Medical Oncology (ESMO) congress by researchers from the National Cancer Center Hospital East (Kashiwa, Japan). This patent grant paves the way for the company to expand both clinical and commercial partnerships and support market entry in the region going forward.
“Japan is a key strategic market for DoMore Diagnostics in the Asian region, with high incidence rate, promising clinical data and partnership discussions. This patent further extends the IP protection of Histotype Px in Asia and reinforces our first-mover advantage in AI-driven digital biomarkers and precision medicine in cancer,” said Torbjørn Furuseth, CEO and Co-Founder of DoMore Diagnostics.
“Colorectal cancer incidence is rising and already the leading cause of cancer deaths in women and the second leading cause in men in Japan, highlighting the urgent need for reliable and scalable biomarkers to guide treatment decisions in this patient population. Together with strong clinical data, the Japanese patent grant means our Histotype Px biomarkers are uniquely positioned to take a leading position in addressing this large unmet medical need.”
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com